Phrontline Biopharma Announces First Patient Dosed in Phase-I Clinical Trial of TJ101
The Phase 1 study of TJ101 will assess its safety, tolerability, pharmacokinetics, and early anti-tumor activity in various solid tumors, using a dose escalation and expansion cohort design.
Phase 1 Clinical Trial | 15/09/2025 | By Dineshwori
Inventiva and Hepalys Pharma Initiate Clinical Development Program of Lanifibranor in Japan
The trial is conducted pursuant to the terms of the exclusive licensing agreement entered into in 2023 between Inventiva and Hepalys to develop and commercialize lanifibranor in Japan and South Korea.
Phase 1 Clinical Trial | 21/02/2025 | By Aishwarya | 305
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy